NCT04483531No Longer Available不适用
Odevixibat (A4250) for the Treatment of Progressive Familial Intrahepatic Cholestasis (Expanded Access Program)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- Albireo
- 试验地点
- 1
研究概览
简要总结
To provide treatment access to patients with PFIC in the US who have pruritus and elevated serum bile acids and who are not able to enroll in A4250-008 (PEDFIC2) for the following reasons: 1) Do not meet eligibility criteria for PEDFIC 2; 2) Are not able to get to a PEDFIC 2 site for geographical reasons, and 3) Do meet the eligibility criteria for PEDFIC 2 after recruitment has been completed
详细描述
Eligible patients will be enrolled into this expanded-access program and treated with an oral dose of 120 μg/kg/day of odevixibat and evaluated on an ongoing basis.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A male or female patient of any age, with a clinical diagnosis of PFIC, and with a body weight ≥5 kg at Screening visit
- •Patient must have a clinical diagnosis of PFIC
- •Patient must have clinically confirmed pruritus
- •Patient must have elevated serum bile acid levels, specifically measured to be ≥2 × the upper limit of normal (ULN) prior to start of medication
- •Patient and/or legal guardian must sign informed consent (and assent) as appropriate. Patients who turn 18 years of age (or legal age per country) during
排除标准
- •Patient is expected to have a liver transplant within 6 months of Screening
- •Decompensated liver disease, coagulopathy, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy
- •International normalized ratio (INR) >1.4 (the patient may be treated with Vitamin K intravenously, and if INR is ≤1.4 at resampling the patient may be started on program medication)
- •Serum ALT >10 × ULN at Screening
- •Serum ALT >15 × ULN at any time point during the last 6 months unless an alternate etiology was confirmed for the elevation
- •Total bilirubin >10 × ULN at Screening
- •Any patient who is pregnant, lactating, or planning to get pregnant
- •Patients who qualify for enrollment in other Phase 2 or Phase 3 trials intended to support marketing approval in PFIC
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb)Peripheral Arterial DiseaseNCT01718288Fadoi Foundation, Italy150
已完成
2 期
4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic AmyloidosisMultiple Myeloma and Plasma Cell NeoplasmNCT00003853National Cancer Institute (NCI)45
Available
不适用
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal InfectionsInvasive Fungal InfectionsNCT06433128Basilea Pharmaceutica
已完成
2 期
Pirfenidone and Advanced Liver Fibrosis.Liver FibrosisChronic Liver DiseaseNCT04099407Grupo Mexicano para el Estudios de las Enfermedades Hepaticas122
已完成
3 期
Treatment Options for Protease Inhibitor-exposed ChildrenHIV/AIDSHIV InfectionsNCT01146873Columbia University300